Acromegaly Market Size was USD 1326.6 million in 2021 and it is expected to rise during the study period (2019-2032) – Digital Journal

The Acromegaly Market is expected to show positive growth in the forecast period (20222032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for emerging therapies.

Acromegaly Market Report gives readers a thorough assessment of key market drivers, restraints, prospects, opportunities, restraints, current trends, and technological and industrial breakthroughs that will influence market growth. This Acromegaly Market report research conducts a careful market evaluation and provides a professional analysis of the industry taking into account market development, present market circumstances, and forecasts for the future. The market driving factors, market overview, industry volume, and market share are also highlighted in this Acromegaly Market report analysis.

Key takeaways from Acromegaly Market Research Report

Know which therapies are expected to grab major Acromegaly Market Share @ Acromegaly Market Research Report

Acromegaly Overview

Acromegaly is a hormonal disorder that results from the availability of excessive growth hormone (GH) in the body, which is produced by the pituitary gland (a small gland in the brain). In acromegaly, the pituitary produces an immoderate amount of GH, which is resulted from benign or noncancerous tumors on the pituitary. These benign tumors are called Adenomas.

Common signs and symptoms of acromegaly are enlarged hands and feet. For example, patients are not able to put on rings that used to fit, and the shoe size has progressively increased. It may also cause gradual changes in the face shape, such as a protruding lower jaw and brow bone, an enlarged nose, thickened lips, and wider spacing between the teeth.

Surgery is the treatment of choice for all microadenomas as well as macroadenomas, causing a mass effect. Debulking of macroadenomas without mass effect can also be done and has been described as a modality to allow for better response to medical treatment even if a surgical cure is not likely. The best predictors of surgical cure include smaller tumor size, lower levels of GH/IGF-1, and absence of invasion of surrounding structures such as the cavernous sinus. All of these drugs are synthetic somatostatin and bind to somatostatin receptors.

Acromegaly Epidemiology Insights

Acromegaly is a very rare disorder caused, in most cases, by a tumor of the pituitary gland that produces too much growth hormone (GH). Nearly all pituitary tumors, including those that cause acromegaly, are benign, and not malignant. However, they can become quite large and expand beyond the normal confines of the pituitary gland.

Acromegaly Epidemiology Segmentation in the 7MM

For further information of this report to understand which factors are driving Acromegaly Epidemiology trends @ Acromegaly Epidemiological Insights

Acromegaly Treatment Market

The current treatment method for Acromegaly is focused on preventing the tumor compression of surrounding tissues by excising the diseases causing areas, and on reducing GH and IGF-1 levels to normal. Although, the primary treatment method for Acromegaly is transsphenoidal surgery, although all the patients are not eligible for surgery. Patients diagnosed with microadenomas and those with macroadenomas not close to other key structures in the brain, such as the nerves supplying the eyes or nearby blood vessels, are recommended for surgery. The cure rate of surgery is about 80% for microadenomas and 4050% for macroadenomas.

Acromegaly Pipeline Companies

Acromegaly Market Insights

As per the literature reviews by Lim et al., titled The role of combination medical therapy in the treatment of acromegaly, pegvisomant and SSA combination has demonstrated good biochemical control in the majority of patients, and may allow individual drug dosage reductions, but patients require close monitoring for liver enzyme elevations. The combination of cabergoline, to SSA is relatively well tolerated and most likely to be effective in patients with very mild IGF-1 elevations. It was also found that the combination of pegvisomant and cabergoline may be useful in a select group of patients with mild IGF-1 elevations, particularly in the setting of intolerance to SSA or when the cost of SSA-Peg therapy is prohibitive.

Learn more about the Acromegaly Therapies in clinical trials @ Drugs for Acromegaly Treatment

Acromegaly Emerging Therapies

The emerging therapies for the treatment of Acromegaly includes Octreotide capsules (Chiasma Pharma), Veldoreotide (Strongbridge Biopharma), CAM2029 (Camurus), CRN00808 (Crinetics Pharmaceuticals), IONIS-GHR-LRx (Ionis Pharmaceuticals), ATL1103 (Antisense Therapeutics), and MTD201 (Midatech). Octreotide capsules have been granted orphan designation in the US and the European Union for the potential treatment of Acromegaly.

Scope of the Acromegaly Market Research Report

Discover more about Acromegaly Medications in development @ Acromegaly Clinical Trials

Table of Content

1. Key Insights

2. Acromegaly Executive Summary

3. Competitive Intelligence Analysis

4. Acromegaly: Market Overview at a Glance

5. Acromegaly: Disease Background and Overview

6. Patient Journey

7. Acromegaly Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Acromegaly Unmet Needs

10. Key Endpoints of Acromegaly Treatment

11. Acromegaly Marketed Products

12. Acromegaly Emerging Therapies

13. Acromegaly: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Acromegaly Market Outlook

16. Access and Reimbursement Overview

17. KOL Views

18. Acromegaly Market Drivers

19. Acromegaly Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Get in touch with our Business Executive @ Acromegaly Market Trend

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/

Read this article:

Acromegaly Market Size was USD 1326.6 million in 2021 and it is expected to rise during the study period (2019-2032) - Digital Journal